This Schedule 14A filing consists of the following press release from Paratek Pharmaceuticals, Inc., a
Delaware corporation (the Company), relating to the Companys special meeting of stockholders to be held on September 18, 2023. The press release was disseminated on September 7, 2023.
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and
Novo Holdings
BOSTON, September 7, 2023 (GLOBE NEWSWIRE) Paratek Pharmaceuticals, Inc. (Paratek) (Nasdaq: PRTK), a
commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy advisor Institutional
Shareholder Services Inc. (ISS) has recommended that stockholders vote FOR the Companys previously announced definitive agreement to be acquired by Gurnet Point Capital (Gurnet Point) and Novo Holdings A/S
(Novo Holdings).
ISS is an independent proxy advisory firm whose clients include many of the worlds leading institutional investors.
Such investors rely on ISSs objective and impartial analysis to make important voting decisions.
We are pleased to receive ISSs
independent recommendation for the transaction. The transaction was the result of a robust process led by the independent members of the Board and offers stockholders immediate value, liquidity, certainty of the upfront cash payment and upside
participation through the CVR. Stockholders are encouraged to vote FOR the transaction today, said Dr. Jeffrey Stein, Ph.D., Lead Independent Director of Parateks board of directors (the Board).
Stockholders are urged to vote online today to ensure their votes are received on time. The deadline for online votes to be received is 11:59pm on
September 17, 2023.
Stockholders who have questions about voting their proxy are encouraged to contact our proxy solicitor Morrow Sodali LLC at +1 (800) 662-5200 (toll-free in North America), +1 (203) 658-9400 (collect outside of North America) or
PRTK@info.morrowsodali.com
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for
life-threatening diseases and other public health threats.
The companys lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial
skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium
abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
Paratek exclusively
licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC.
Paratek retains the development and commercialization rights for sarecycline in the rest of the world.